Lemaitre Vascular (LMAT) EBIT Margin (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of EBIT Margin data on file, last reported at 26.71% in Q1 2026.

• On a quarterly basis, EBIT Margin rose 562.0% year-over-year to 26.71% in Q1 2026; TTM through Mar 2026 was 28.51%, a 508.0% increase from a year earlier, with the FY2025 full-year figure at 27.21%, up 344.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 26.71%, down from 29.22% in the prior quarter.
• Over the last five years, EBIT Margin for LMAT reached as high as 33.27% in Q3 2025 and fell as low as 13.74% in Q2 2022.
• Historically, EBIT Margin has averaged 21.93% across 5 years, with a median of 21.09% in 2025.
• Across the five-year window, EBIT Margin sank 1357 bps in 2022 and soared 929 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 17.01% in 2022, then climbed by 23 bps to 20.88% in 2023, then advanced by 10 bps to 23.07% in 2024, then grew by 27 bps to 29.22% in 2025, then slipped by 9 bps to 26.71% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 26.71% in Q1 2026, 29.22% in Q4 2025, and 33.27% in Q3 2025.